AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SGHT · NASDAQ · Medical - Devices

Sight Sciences

Develops interventional devices for glaucoma surgery and dry eye treatment.

$8.55

After-hours close+0.02 (+0.23%)

At close$8.53(+1.43%)

Something off on this page? Send us feedback.

Profile

Sight Sciences, Inc.SGHTHealth Care

Sells OMNI and SION devices for interventional glaucoma and TearCare for evaporative dry eye. Revenue is concentrated in the United States and mainly comes from glaucoma products sold to hospitals, medical centers, and eyecare professionals.

Built around interventional ophthalmic procedures, the business sells OMNI products, including OMNI Edge and Ergo Series systems, plus the SION Surgical Instrument for glaucoma procedures. TearCare and related components address evaporative dry eye linked to meibomian gland dysfunction.

Sales are concentrated in the United States, primarily through representatives and distributors serving hospitals, medical centers, and eyecare professionals. The commercial base is anchored by glaucoma products, while dry eye remains tied to broader reimbursement and market-access work.

Execution depends on physician training, practice patterns, patient selection, and payer coverage for the relevant procedures. Competition includes other MIGS products and dry-eye treatment systems, so adoption is shaped by clinical workflow, reimbursement timing, and new product activity.

Company facts

CEOPaul Badawi

ListedJul 15, 2021

ExchangeNASDAQ

HeadquartersMenlo Park, CA

CountryUnited States

Employees186

CIK0001531177

ISINUS82657M1053

Key statistics

Market cap$465.2M

EPS (ttm)−$0.5584

P/E (ttm)−15.31

ROE-50.6%

P/B8.81

P/S5.58

Dividend yield—

Beta1.82vs XLV 1.07

Year to date +14.0% · Average volume (30d) 267.7K

Analysts

Price target, next 12 months$7.50−12.3%Median of 9 analysts · vs the Aug 28 close

ConsensusBuy4 of 9 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $8.55

High$8.00−6.4%

Median$7.50−12.3%

Low$7.00−18.1%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jul 28, 2026	UBS	Target			$12	$7
Mar 2, 2026	Cantor Fitzgerald	Target				$8
Jan 5, 2026	Piper Sandler	Upgrade	Neutral	Overweight	$4	$9
Jan 5, 2026	Raymond James	Target				$9
Dec 22, 2025	UBS	Target				$12

Earnings

EPS

Estimate−$0.13

ReportedDue Nov 5, 2026

Revenue

Estimate$23.6M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.18	−$0.08	+56.4%	$21.7M	$23.4M	+7.7%	+27.75%
May 6, 2026Q1 FY26	−$0.19	−$0.16	+15.8%	$18.5M	$19.7M	+6.7%	+23.02%
Mar 4, 2026Q4 FY25	−$0.15	−$0.08	+46.7%	$20.3M	$20.4M	+0.2%	−26.80%
Nov 6, 2025Q3 FY25	−$0.26	−$0.16	+38.5%	$20.4M	$19.9M	−2.2%	+16.40%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$17.5M	$19.6M	$19.9M	$20.4M	$19.7M	$23.4M
Gross profit	$15.1M	$16.6M	$17.2M	$17.8M	$17.0M	$21.4M
Operating income	−$13.9M	−$11.7M	−$7.9M	−$3.7M	−$12.4M	−$3.9M
Net income	−$14.2M	−$11.9M	−$8.2M	−$4.2M	−$13.0M	−$4.4M
Diluted EPS	−$0.28	−$0.23	−$0.16	−$0.08	−$0.24	−$0.08
Gross margin	86.2%	84.8%	86.4%	87.3%	86.2%	91.4%
Operating margin	-79.2%	-59.6%	-39.7%	-18.0%	-63.0%	-16.6%

Fiscal years (4-quarter sums)FY21 $49.0M · FY22 $71.3M · FY23 $81.1M · FY24 $79.9M · FY25 $77.4M

Revenue by product · Q2 FY26

Surgical Glaucoma$20.7M · 89%

Dry Eye$2.7M · 11%

Balance sheet, Jun 30, 2026Cash & short-term investments $79.8M · Total debt $42.0M · Total assets $104.9M · Shareholders' equity $52.9M

Dividends

No dividends on record.

Ownership

Institutions 41.40%22.52M sharesInsiders 33.21%18.07M sharesOther 25.39%13.82M shares

Shares outstanding 54.41M · Float 35.12M · 64.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Staffan Encrantz · director, 10 percent owner:	6.52M	11.99%	Form 4	Jun 11, 2026
Paul Badawi · director, 10 percent owner, officer: President and CEO	6.12M	11.25%	Form 4	Jul 6, 2026
Long Focus Capital Management, LLC	3.59M	6.61%	13F	May 15, 2026
BlackRock, Inc.	2.83M	5.20%	13F	May 13, 2026
Pathstone Holdings, LLC	2.40M	4.41%	13F	May 11, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jul 1, 2026	Paul Badawi	director, 10 percent owner, officer: President and CEO	−28,684	$5.42
Jul 2, 2026	Alison Bauerlein	officer: Chief Operating Officer	−24,184	$5.36
Jul 1, 2026	Brenton Taylor	officer: EVP, Operations & R&D	−2,829	$5.42
Jul 6, 2026	David Badawi	director, officer: Chief Technology Officer	−7,418	$5.51
Jul 2, 2026	James Rodberg	officer: Chief Financial Officer	−6,902	$5.36